Clinical Trials
39 trialsVemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
POSIBA
Grupo Espanol Multidisciplinario del Cancer Digestivo
OPALO
Grupo Espanol Multidisciplinario del Cancer Digestivo
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
SWOG Cancer Research Network
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Massachusetts General Hospital
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Eli Lilly and Company
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
mAbxience Research S.L.
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
University Health Network, Toronto
AXEPT
Epidemiological and Clinical Research Information Network
RS CAMPTO
Institut Cancerologie de l'Ouest
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
University of Washington
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
Alliance for Clinical Trials in Oncology
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase I Trial of Combination of FOLFIRI and SOM 230
H. Lee Moffitt Cancer Center and Research Institute
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Gustave Roussy, Cancer Campus, Grand Paris
COMETS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer
Fudan University
ERBIFORT
National Cancer Institute, France
VELOUR
Sanofi
MIROX
GERCOR - Multidisciplinary Oncology Cooperative Group
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Institutes of Health Clinical Center (CC)
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
TIROX2
National Cancer Center, Korea
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
Johannes Gutenberg University Mainz
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
Charite University, Berlin, Germany